Role of molecular-genetic tests for adjuvant chemotherapy of patients with breast cancer

Currently, there are several commercially available multigenomic tests that can be used for decision-making concerning adjuvant chemotherapy of patients with breast cancer. These tests include Oncotype Dx, MammaPrint, Prosigna (PAM 50), and EndoPredict. While all these available tests have a high sensitivity and high negative predictive value, they suffer significantly from low specificity and low positive predictive value.During the presentation, advantages and limitations of each test will be critically reviewed. A practical approach in dealing with the use of a multigenomic test will be provided.